Investigation of standardized administration of anti‑platelet drugs and its effect on the prognosis of patients with coronary heart disease

The aim of the present study was to explore the effect of adherence to standardized administration of anti‑platelet drugs on the prognosis of patients with coronary heart disease. A total of 144 patients newly diagnosed with coronary heart disease at Lu'an Shili Hospital of Anhui Province (Lu'an, China) between June 2010 and June 2012 were followed up. Kaplan‑Meier curves and the Cox regression model were used to evaluate the effects of standardized administration of anti‑platelet drugs on primary and secondary end‑point events. Of the patients with coronary heart disease, 109 (76%) patients took standard anti‑platelet drugs following discharge. Kaplan‑Meier curve and Cox regression analysis showed that standardized administration of anti‑platelet drugs reduced the risk of primary end‑point events (including all‑cause mortality, non‑lethal myocardial infarction and stroke) of patients with coronary heart disease [hazard ratio (HR)=0.307; 95% confidence interval (CI): 0.099‑0.953; P=0.041) and all‑cause mortality (HR=0.162; 95% CI: 0.029‑0.890; P=0.036); however, standardized administration had no predictive value with regard to secondary end‑point events. Standardized administration of anti‑platelet drugs obviously reduced the risk of primary end‑point events in patients with coronary heart disease, and further analysis showed that only all‑cause mortality exhibited a statistically significant reduction.